[go: up one dir, main page]

UY32041A - Sistema de administración de drogas con contenido de progestina - Google Patents

Sistema de administración de drogas con contenido de progestina

Info

Publication number
UY32041A
UY32041A UY0001032041A UY32041A UY32041A UY 32041 A UY32041 A UY 32041A UY 0001032041 A UY0001032041 A UY 0001032041A UY 32041 A UY32041 A UY 32041A UY 32041 A UY32041 A UY 32041A
Authority
UY
Uruguay
Prior art keywords
progestin
progestine
content
drug administration
administration system
Prior art date
Application number
UY0001032041A
Other languages
English (en)
Inventor
Bracht Stefan
Funke Adrian
General Sascha
Terebesi Lldiko
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/000904 external-priority patent/WO2009100871A2/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32041A publication Critical patent/UY32041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones de administración de drogas en forma de películas delgadas solubles en agua (obleas), que contienen partículas que comprenden al menos una progestina y al menos un agente protector. El agente protector provee el enmascaramiento efectivo del sabor de la progestina debido a la liberación limitada de la progestina en la boca. Por consiguiente, la progestina no es absorbida a través de la ruta bucal, sino que lo es a través de la ruta entérica (peroral).
UY0001032041A 2008-08-08 2009-08-10 Sistema de administración de drogas con contenido de progestina UY32041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08162105 2008-08-08
PCT/EP2009/000904 WO2009100871A2 (en) 2008-02-13 2009-02-10 Drug delivery system with stabilising effect

Publications (1)

Publication Number Publication Date
UY32041A true UY32041A (es) 2010-03-26

Family

ID=40210465

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032041A UY32041A (es) 2008-08-08 2009-08-10 Sistema de administración de drogas con contenido de progestina

Country Status (23)

Country Link
US (1) US20110293720A1 (es)
EP (1) EP2331067A1 (es)
JP (1) JP2011530499A (es)
KR (1) KR20110044752A (es)
CN (1) CN102119021A (es)
AR (1) AR072933A1 (es)
AU (1) AU2009279053A1 (es)
BR (1) BRPI0917030A2 (es)
CA (1) CA2732211A1 (es)
CO (1) CO6351709A2 (es)
CR (1) CR20110072A (es)
DO (1) DOP2011000049A (es)
EA (1) EA201100304A1 (es)
EC (1) ECSP11010815A (es)
IL (1) IL210590A0 (es)
MA (1) MA32538B1 (es)
MX (1) MX2011001519A (es)
PE (1) PE20110573A1 (es)
SV (1) SV2011003835A (es)
TW (1) TW201008569A (es)
UY (1) UY32041A (es)
WO (1) WO2010015713A1 (es)
ZA (1) ZA201101737B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086989A1 (ja) 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
HUP0900698A2 (en) * 2009-11-06 2011-06-28 Richter Gedeon Nyrt Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation
JP5588688B2 (ja) * 2010-01-28 2014-09-10 日東電工株式会社 フィルム状製剤
JP2011207847A (ja) * 2010-03-30 2011-10-20 Nitto Denko Corp フィルム状製剤及びその製造方法
JP5751868B2 (ja) 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
PH12014500235A1 (en) 2011-09-09 2022-05-02 Philip Morris Products Sa Smoking article comprising a flavour delivery material
US9044734B2 (en) 2011-09-23 2015-06-02 Basf Se Diesel oxidation catalyst with layered structure containing ceria composition as palladium support material for enhanced HC and CO gas conversion
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
JP5952646B2 (ja) * 2012-06-07 2016-07-13 救急薬品工業株式会社 口腔内溶解型フィルム製剤
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
CN104379174B (zh) * 2012-06-22 2018-01-26 巴斯夫欧洲公司 基于甲基丙烯酸二乙基氨基乙酯共聚物的含活性成分固体分散体
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN103040725B (zh) * 2012-12-26 2015-01-21 武汉九珑人福药业有限责任公司 一种利用研磨改善屈螺酮溶出的方法及屈螺酮固体分散体
JP6084468B2 (ja) * 2013-01-24 2017-02-22 アリメント工業株式会社 シビレ緩和持続性唾液分泌促進剤、その製造方法、及びシビレ緩和持続性唾液分泌促進食品
KR101407922B1 (ko) * 2013-11-14 2014-06-17 주식회사 서울제약 약리학적 활성 성분을 포함하는 다공성 구강붕해필름 및 이의 제조방법
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US20160243036A1 (en) * 2015-02-25 2016-08-25 Intelgenx Corp. Film dosage forms containing amorphous active agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN108606963B (zh) * 2017-12-27 2021-05-18 上海长海医院 含有屈螺酮和雌激素的复方避孕贴、制备方法及应用
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
CN108853017B (zh) * 2018-09-17 2021-03-02 西安力邦医药科技有限责任公司 一种雌三醇纳米口服制剂的组方与制备工艺
EP3954364A1 (en) * 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition
CA3194494A1 (en) 2020-09-29 2022-04-07 Millicent Pharma Limited Orodispersible formulations
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN119925640A (zh) * 2025-02-13 2025-05-06 国家卫生健康委科学技术研究所 一种控释药物组合物的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769854B1 (fr) * 1997-10-21 2000-03-31 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
WO2004098561A2 (en) * 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
EP1933811A2 (en) * 2005-09-30 2008-06-25 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen

Also Published As

Publication number Publication date
CN102119021A (zh) 2011-07-06
CO6351709A2 (es) 2011-12-20
AU2009279053A1 (en) 2010-02-11
JP2011530499A (ja) 2011-12-22
WO2010015713A1 (en) 2010-02-11
AR072933A1 (es) 2010-09-29
CA2732211A1 (en) 2010-02-11
EA201100304A1 (ru) 2011-08-30
DOP2011000049A (es) 2011-03-15
KR20110044752A (ko) 2011-04-29
MA32538B1 (fr) 2011-08-01
SV2011003835A (es) 2011-07-01
CR20110072A (es) 2011-03-30
MX2011001519A (es) 2011-03-29
PE20110573A1 (es) 2011-08-12
BRPI0917030A2 (pt) 2017-03-21
US20110293720A1 (en) 2011-12-01
ZA201101737B (en) 2013-08-28
EP2331067A1 (en) 2011-06-15
ECSP11010815A (es) 2011-03-31
TW201008569A (en) 2010-03-01
IL210590A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
UY32041A (es) Sistema de administración de drogas con contenido de progestina
WO2014130866A3 (en) Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles
AR070379A1 (es) Sistema de administracion de drogas con efecto estabilizante
MX2010003642A (es) Nanotecnologia de vacuna.
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
UY31957A (es) Metodo anticonceptivo mejorado
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
ATE474564T1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MX2009012858A (es) Vacuna para la prevencion de recaidas de cancer de seno.
ECSP088240A (es) Composición de trazodona para administración una vez por día
BR112018068642A2 (pt) composição e uso de composição
UA111599C2 (uk) Композиція каспофунгіну
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
MY172788A (en) Influenza vaccines
NZ601890A (en) Treatment or prevention of infection
MX2015007794A (es) Suministro transmucosal de acetato de glatiramer mediante parches orales.
CU20110036A7 (es) Sistema de administración de drogas que contiene progestina
CO6290633A2 (es) Sistema de administracion de drogas que contieen estra-diol
AR080541A1 (es) Tratamiento para la endometriosis
WO2016014680A8 (en) Oral transmucosal compositions including aromatase inhibitors for low testosterone levels in men
MY206419A (en) Hepatitis b vaccine transnasal administration system

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181112